胃泌素瘤 中国就医指南

Gastrinoma is a rare, neuroendocrine tumor that secretes excessive amounts of gastrin—typically arising from the duodenum (60–70%) or pancreas (20–30%), and less commonly from gastric, jejunal, or lymph node tissue. It is the principal cause of Zollinger–Ellison syndrome (ZES), characterized by profound gastric acid hypersecretion, recurrent peptic ulcer disease, gastroesophageal reflux, diarrhea, and malabsorption. Pathogenically, gastrinomas originate from enterochromaffin-like (ECL) cells or gastrin-producing G-cells in the antrum or duodenal Brunner’s glands. Most sporadic cases involve somatic mutations in genes such as MEN1, CDKN1B, or DAXX/ATRX; approximately 20–25% occur in the context of multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder with germline MEN1 gene mutations. Tumor behavior varies: while ~60–70% are malignant at diagnosis (with hepatic or lymph node metastases), duodenal tumors tend to be smaller and less aggressive than pancreatic ones. Epidemiologically, gastrinoma incidence is estimated at 0.5–2 cases per million person-years, with a median age at diagnosis of 50–60 years and slight male predominance (M:F ≈ 1.5:1). Risk factors include familial MEN1 syndrome, prior gastric surgery (e.g., vagotomy), chronic atrophic gastritis, and possibly long-standing proton pump inhibitor (PPI) use—though causality remains unproven. Diagnosis hinges on elevated fasting serum gastrin (>1000 pg/mL), gastric acid hypersecretion (basal acid output >15 mEq/h), and provocative testing (e.g., secretin stimulation test); imaging (EUS, SRS, Ga-68 DOTATATE PET/CT) localizes tumors. Untreated, gastrinoma significantly impairs quality of life: chronic abdominal pain, debilitating diarrhea, weight loss, nutritional deficiencies (e.g., iron, B12, calcium), fatigue, and anxiety related to recurrent ulcers or cancer progression are common. Even with treatment, lifelong PPI therapy is often required, and patients face surveillance burdens, surgical morbidity, and psychosocial stress—including concerns about malignancy, hereditary risk for family members, and limitations in diet, travel, and work due to GI instability. Early detection and multidisciplinary management (endocrinology, gastroenterology, oncology, surgery) markedly improve outcomes and functional status.

# 胃泌素瘤（Zollinger-Ellison综合征）治疗方案与费用明细（内分泌科）

一、非手术/药物保守治疗（适用于不可切除、转移性或术前准备患者）

• •质子泵抑制剂（PPI）维持治疗：奥美拉唑/埃索美拉唑肠溶片，日剂量20–120 mg，年药费 ¥1,800–¥6,500（国产至原研）
• •辅助检查费：胃液pH监测+血清胃泌素测定（空腹及激发试验）+胰腺MRI增强+EUS-FNA，单次 ¥2,200–¥4,800

二、手术治疗（根治性首选，适用于局限性原发灶、无远处转移者）

• •腹腔镜胰十二指肠切除/局部剜除术：需术前定位（EUS/奥曲肽显像），术前检查（增强CT+肝功能+心肺评估） ¥3,500–¥5,200；手术+住院（7–12天）总费用 ¥85,000–¥148,000（含麻醉、病理、ICU备用）

三、特殊复杂情况处理

• •肝多发转移/耐药进展期：PRRT（¹⁷⁷Lu-DOTATATE）治疗（2–4周期），单周期 ¥98,000–¥126,000；靶向药舒尼替尼（二线）年药费 ¥156,000–¥220,000（医保谈判后自付约¥32,000–¥58,000）

四、方案快速选择指南

• •预算有限、初诊高胃泌素血症者 → 首选PPI+规范检测（总启动成本≤¥8,000）
• •可手术、无转移者 → 微创根治术（性价比最优，治愈率>75%）
• •晚期伴肝转移、症状难控者 → PRRT联合PPI（优先纳入国家医保特药通道）